Every letter we have printed

Nobody has defined what custody means in a market where the buyer is an individual and the laboratory is on another continent. Importing the phrase from clinical practice without importing the institutions has produced a word with no local meaning.

Reasons given in public forums are shaped by the audience. A community that values persistence will hear fewer accounts of stopping, and a community that is sceptical will hear more. Neither is a sample of anything.

Cost is the reason least often recorded and most often given in private. Every survey I have seen collapses it into an "other" category, and it is very likely the largest single entry in the list.

Every long arrangement eventually meets a life event that interrupts it — a move, an illness, a change of circumstances. The literature treats interruption as non-adherence; the accounts I read treat it as ordinary life, and the two vocabularies describe the same events.

Extrapolating a composition ratio to a different rate of loss is the error I see most often. The relationship is not linear in any dataset I have read, and applying a percentage from a slow-loss cohort to a fast-loss one has no support at all.

Bariatric surgical cohorts are the other borrowed population and the mechanism differs substantially. Findings that follow from altered anatomy do not automatically follow from reduced intake, and the two literatures are frequently quoted side by side as though they were one.

The plateau discussion in community settings has a strong survivorship character. People whose trajectory continued do not post about a plateau, so the visible discussion overstates how universal the experience is.

The composition question sits underneath the plateau question and is almost never asked with it. A flat mass curve can conceal a continuing change in composition in either direction, and the scale on the floor cannot distinguish them.

Material sold for research use is not approved for human use in any jurisdiction, and a discussion of ceilings in that context is a discussion about what has been studied rather than about what anybody should do. Your department is consistent on this and it is why I trust the rest of the coverage.

Your residual-exposure table gives six per cent after four weeks. I calculate 6.25 per cent, which is a quibble, but the larger point is that it assumes steady state at the moment of interruption. Someone who stops three weeks into a new rung has less on board than your table implies.

The four-week interval is not arbitrary and your article explains why better than the labels do. With a half-life of about a week, four weeks is roughly the time to steady state, so a shorter interval escalates onto a concentration that has not finished rising. That is the arithmetic, and it deserves to be quoted whenever the interval is questioned.

Resistance training during an energy deficit attenuates lean tissue loss rather than preventing it, and the honest framing is attenuation. Overstating what training can achieve sets an expectation that the evidence does not support and that people then blame themselves for missing.

A short note on reporting. Where a study reports training volume, it should report it in a form somebody could reproduce: sessions, exercises, sets and progression. Most report a duration in weeks and nothing else.

You write that no trial has measured strength. There are observational cohorts with grip strength data. Why do you insist on randomised measurement?

The target dose and the maximum dose are different concepts and the trade uses them as synonyms. A target is where the trial aimed; a maximum is where the label stops. Somebody doing well below the target has not failed to reach anything.

Trials that permitted escalation after a plateau and trials that did not are compared as though the protocols were the same. The escalation rule is one of the strongest determinants of the shape of the published curve.

Thank you for saying plainly that the maximum dose is not the goal. I stopped at 10 mg fourteen months ago because it was working and I was tired of arguing about it. Every article I read before yours implied I had given up early.

Trials that included a structured activity component and trials that did not are compared directly in most coverage, and the component is one of the largest determinants of the composition outcome. It should be the first thing in any comparison table.

The resistance training literature has decades of work on preserving lean mass during energy deficit, and this field barely cites it. The two bodies of work would inform each other considerably.

Three vendors have now sent me marketing material claiming their product preserves lean mass during GLP-1 treatment, two of them citing your publication as a source for the underlying composition figures. You may want to know that.

The hundred-unit convention is the source of more confusion than anything else in this subject, because the graduation is a volume marking that was designed for a different drug at a fixed concentration. On a syringe marked to a hundred units, one unit is a hundredth of a millilitre and nothing else. Everything downstream follows from that single sentence.

Community calculators are widely used and almost none of them show their working. A tool that produces a number without the intermediate steps cannot be checked, and the checking is the part that catches the error.

Your needle-length section says four millimetres is adequate for all adults, which contradicts what I was told by a nurse who insisted on half an inch because of my weight. Which is right?

The relevant literature here is nursing and pharmacy practice rather than anything specific to this market, and it is freely available. Almost nobody discussing this subject has read any of it.

Please continue to state plainly what has not been established. It is the part of your reporting I have come to rely on most.

Nobody publishes the distribution, only the proportion. Whether effects are mild across most of a population or severe in a small part of it is the question a reader has, and an incidence figure cannot answer it either way.

In this market the dose is a calculation performed by the buyer from a concentration they inferred, which introduces a source of variation absent from any trial. Anything read across from the trial literature carries that additional uncertainty.

Spontaneous reporting systems undercount by a factor nobody can pin down, and the databases are used in public argument as though they were registries. A note on what a voluntary reporting system can and cannot support would be a useful reference entry.

I want to push back on the ginger paragraph. You describe the evidence as transferred from pregnancy and chemotherapy, which is accurate, and then include it in the table anyway. Either it belongs or it does not.

Regulatory documents are public, detailed and readable, and they contain the tabulated safety data that news coverage summarises badly. Pointing readers at the primary document is more useful than another summary of it.

One request for the checklist. Ask whether the stability data supporting the storage statement was generated on this formulation or on the same peptide in a different one. The distinction decides whether the number applies to the vial in your hand.

Ask which indicator and at what threshold. There are several products with very different trigger conditions and the carton usually says only that one is present.

Long-term receptor pharmacology is genuinely unknown territory, and the honest statement is that the exposure durations now being contemplated exceed the durations that have been studied. That is not alarming and it is not nothing, and it should be said in both those registers at once.

A mechanistic argument can be tested only where an outcome study exists to test it against, and in this class several widely repeated mechanistic claims have never met one. Listing which have and which have not would be a useful reference entry.

Selectivity against the glucagon and GIP receptors is usually quoted as a ratio without saying what assay produced it. Binding affinity and functional potency give different ratios on the same pair of molecules, and the two are used interchangeably in promotional material.

Half-maximal values from different assay formats can differ by an order of magnitude for the same ligand, which makes any table without the assay method close to decorative.

Maintenance is discussed almost entirely in terms of what is taken and almost never in terms of what is measured. A phase defined by stability needs a monitoring plan more than an acute phase does, and I see far less written about the second.

Maintenance at a reduced dose has a thin evidence base compared with the escalation and target-dose literature, which is the opposite of where most people spend their time. That imbalance deserves stating every time maintenance is discussed.

Reasons collected by a supplier, a clinician and a researcher would produce three different distributions from the same population, because people say different things to different audiences. Every dataset in this area is an artefact of who was asking.

An argument for writing about this at all: people are making long commitments now, on information collected over shorter periods, and a publication that keeps saying how long the evidence runs is doing something useful even when it has nothing new to report.